ArriVent BioPharma, Inc.
corporate_fare Company Profile
ArriVent BioPharma, Inc. (NASDAQ:AVBP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for AVBP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for AVBP spans 10-Q, 8-K, 424B5, DEF 14A.
Recent high-impact activity:
- ArriVent 10-Q: $40.3M Q3 Loss, $393.2M Cash to Mid-2028, Firmonertinib Patent Claims Confirmed
- ArriVent Posts $40.3M Q3 Loss, $393.2M Cash to Mid-2028; R&D Chief Lutzker to Retire
- ArriVent Posts $40.3M Q3 Loss, $393M Cash Through Mid-2028 as FURVENT Review Continues
- ArriVent's ARR-217 ADC Shows 44.8% ORR in Late-Line CRC at ESMO 2026
- ArriVent Doses First Patient in Phase 1 Trial of Dual-Target ADC ARR-002
Financial Snapshot
Short Interest & Short Volume
3.43 days to coverFINRA reported short interest of 5,797,018 shares in AVBP as of the October 30, 2026 settlement, a 14.8% decrease from the prior period — about 3.4 days to cover at its recent average daily volume. On November 20, 2026, 52.2% of AVBP volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.